Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BioVaxys (BIOV) has acquired TAETSoftware, a Vancouver-based clinical studies management company
  • TAETSoftware is developing a software application for clinical study subjects to record and submit Adverse Drug Events reports to study sponsors in real time
  • Consideration includes 24,500,000 common shares, with an additional 2,500,000 common shares payable upon the successful testing of the application’s beta version
  • CEO James Passin joined Coreena Robertson to discuss the news
  • Additionally, BioVaxys closed a private placement consisting of 5,360,000 common shares priced at $0.125 for gross proceeds of $670,000
  • Vancouver-based BioVaxys is a clinical-stage biotechnology company developing viral and oncology vaccine platforms, as well as immuno-diagnostics
  • BioVaxys Technology (BIOV) opened unchanged trading at $0.07 per share

BioVaxys (BIOV) has acquired TAETSoftware, a Vancouver-based clinical studies management company.

TAETSoftware is developing its Trial Adverse Events Tracker technology platform, a proprietary software application for clinical study subjects to record and submit Adverse Drug Events (ADEs) reports to study sponsors in real time.

The solution is a step up in efficiency from paper-based reporting, which is limited by under-reporting, poorly documented reporting and reporting delays.

Consideration includes 24,500,000 common shares, with an additional 2,500,000 common shares payable upon the successful testing of the application’s beta version.

BioVaxys is evaluating the potential to offer blinded demographic and disease data to companies interested in healthcare analytics and data mining.

CEO James Passin joined Coreena Robertson to discuss the news.

Additionally, BioVaxys has closed a private placement consisting of 5,360,000 common shares priced at $0.125 for gross proceeds of $670,000. All issued shares are subject to a statutory hold period of four months and one day. The company intends to use the proceeds for working capital.

Vancouver-based BioVaxys is a clinical-stage biotechnology company developing viral and oncology vaccine platforms, as well as immuno-diagnostics.

BioVaxys Technology (BIOV) opened unchanged trading at $0.07 per share.


More From The Market Herald
The Market Herald Video

" Trillion Energy’s (CSE:TCF) Bayhanli-2 gas well enters production

Trillion Energy International Inc. (CSE: TCF) (

" WELL Health NCIB suggests undervaluation

WELL Health has entered into an automatic share purchase plan to facilitate share repurchases.
The Market Herald Video

" Nextech3D.ai (C.NTAR) (NEXCF) Showcases Its Patent Pending Groundbreaking AI for Fixed Point Diffusion of 2D to 3D Model Conversion

Nextech3D.
The Market Herald Video

" ARway.ai (C.ARWY) (ARWYF) Announces Cross Platform Compatibility Across Magic Leap & Hololens As it Prepares For Additional AR Glasses Compatibility

ARway.